CD19 and lymphoma: Since some patients can develop antigen escape over time, the persistence of CD19 CAR T cells would perpetuate the immunoglobulin deficiency without any anti‐leukaemia/lymphoma benefit, which is not a concern with CAR transfected NK‐92 cells that have a limited life span in the circulation.